Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosa

被引:35
作者
Eagye, Kathryn J. [1 ]
Kuti, Joseph L. [1 ]
Nicolau, David P. [1 ,2 ]
机构
[1] Hartford Hosp, Ctr Anti Infect Res & Dev, Hartford, CT 06102 USA
[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA
关键词
ANTIBIOTIC-RESISTANCE; NOSOCOMIAL INFECTIONS; KLEBSIELLA;
D O I
10.1086/603527
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE. To determine risk factors and outcomes for patients with meropenem high-level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] >= 32 mu g/mL). DESIGN. Case-control-control. SETTING. An 867-bed urban, teaching hospital. PATIENTS. Fifty-eight MRPA case patients identified from an earlier P. aeruginosa study; 125 randomly selected control patients with meropenem-susceptible P. aeruginosa (MSPA) (MIC <= 4 mu g/mL), and 57 control patients without P. aeruginosa (sampled by case date/location). METHODS. Patient data, outcomes, and costs were obtained via administrative database. Cases were compared to each control group while controlling for time at risk (days between admission and culture, or entire length of stay [LOS] for patients without P. aeruginosa). RESULTS. A multivariable model predicted risks for MRPA versus MSPA (odds ratio [95% confidence interval]): more admissions (in the prior 12 months) (1.41 [1.15, 1.74]), congestive heart failure (2.19 [1.03, 4.68]), and Foley catheter (2.53 [1.18, 5.45]) (adj. R-2 = 0.28). For MRPA versus no P. aeruginosa, risks were age ( in 5-year increments) (1.17 [1.03, 1.33]), more prior admissions (1.40 [1.08, 1.81]), and more days in the intensive care unit (1.10 [ 1.03, 1.18]) ( adj. R-2 = 0.32). Other invasive devices (including mechanical ventilation) and previous antibiotic use (including carbapenems) were nonsignificant. MRPA mortality (31%) did not differ from that of MSPA (15%) when adjusted for time at risk (P = .15) but did from mortality without P. aeruginosa (9%) (P = .01). Median LOS and costs were greater for MRPA patients versus MSPA patients and patients without P. aeruginosa: 30 days versus 16 and 10 (P < .01) and $88,425 versus $28,620 and $22,605 (P < .01). CONCLUSIONS. Although antibiotic use has been shown to promote resistance, our data found that prior antibiotic use was not associated with MRPA acquisition. However, admission frequency and Foley catheters were, suggesting that infection control measures are essential to reducing MRPA transmission.
引用
收藏
页码:746 / 752
页数:7
相关论文
共 15 条
[1]  
El Amin N, 2005, APMIS, V113, P187, DOI 10.1111/j.1600-0463.2005.apm1130306.x
[2]   Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998 [J].
Fluit, AC ;
Jones, ME ;
Schmitz, FJ ;
Acar, J ;
Gupta, R ;
Verhoef, J .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) :454-460
[3]   Overview of nosocomial infections caused by gram-negative bacilli [J].
Gaynes, R ;
Edwards, JR .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) :848-854
[4]   Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients [J].
Harris, AD ;
Smith, D ;
Johnson, JA ;
Bradham, DD ;
Roghmann, MC .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) :340-345
[5]   Resistance patterns among nosocomial pathogens - Trends over the past few years [J].
Jones, RN .
CHEST, 2001, 119 (02) :397S-404S
[6]   Reference group choice and antibiotic resistance outcomes [J].
Kaye, KS ;
Engemann, JJ ;
Mozaffari, E ;
Carmeli, Y .
EMERGING INFECTIOUS DISEASES, 2004, 10 (06) :1125-1128
[7]   Antibiotic resistance in the intensive care unit [J].
Kollef, MH ;
Fraser, VJ .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (04) :298-314
[8]   Imipenem resistance among Pseudomonas aeruginosa isolates:: Risk factors for infection and impact of resistance on clinical and economic outcomes [J].
Lautenbach, Ebbing ;
Weiner, Mark G. ;
Nachamkin, Irving ;
Bilker, Warren B. ;
Sheridan, Angela ;
Fishman, Neil O. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2006, 27 (09) :893-900
[9]   Of Pseudomonas, porins, pumps and carbapenems [J].
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) :247-250
[10]   Nosocomial infections in medical intensive care units in the United States [J].
Richards, MJ ;
Edwards, JR ;
Culver, DH ;
Gaynes, RP .
CRITICAL CARE MEDICINE, 1999, 27 (05) :887-892